Using novel biological therapies to target a tumor-specific isoform of HER2 for the treatment of advanced breast cancer
Active Project Grant Awarded Last action
- Award ID
- HT9425261E067
- Recipient
-
University Of Melbourne UEI P8JJC89CWNK5
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,121,554
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 21% complete
- Place of performance
- Australia
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded the University of Melbourne $1,121,554 on April 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop novel biological therapies targeting a tumor-specific isoform of HER2 for treatment of advanced breast cancer. The award obligates $1,121,554 through March 31, 2029. Work is performed in Australia. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative research and investigation of medical solutions for battlefield and clinical applications.
Quick answers
Who received award HT9425261E067?
HT9425261E067 was awarded to University Of Melbourne by Defense Health Agency (Department of Defense) on April 1, 2026.
How much is award HT9425261E067 worth?
$1,121,554 has been obligated on HT9425261E067.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award